EP1427855A4 - Method and reagents for identifying gene targets for treating breast cancer - Google Patents
Method and reagents for identifying gene targets for treating breast cancerInfo
- Publication number
- EP1427855A4 EP1427855A4 EP02761122A EP02761122A EP1427855A4 EP 1427855 A4 EP1427855 A4 EP 1427855A4 EP 02761122 A EP02761122 A EP 02761122A EP 02761122 A EP02761122 A EP 02761122A EP 1427855 A4 EP1427855 A4 EP 1427855A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reagents
- breast cancer
- treating breast
- gene targets
- identifying gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30673001P | 2001-07-20 | 2001-07-20 | |
US306730P | 2001-07-20 | ||
WOPCT/US02/06254 | 2002-02-28 | ||
PCT/US2002/006254 WO2003008578A2 (en) | 2001-07-20 | 2002-02-28 | Reagents and methods for identifying gene targets for treating cancer |
PCT/US2002/022868 WO2003007884A2 (en) | 2001-07-20 | 2002-07-19 | Method and reagents for identifying gene targets for treating breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1427855A2 EP1427855A2 (en) | 2004-06-16 |
EP1427855A4 true EP1427855A4 (en) | 2005-04-20 |
Family
ID=23186592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02761122A Withdrawn EP1427855A4 (en) | 2001-07-20 | 2002-07-19 | Method and reagents for identifying gene targets for treating breast cancer |
Country Status (6)
Country | Link |
---|---|
US (2) | US7235403B2 (en) |
EP (1) | EP1427855A4 (en) |
JP (2) | JP2005516586A (en) |
AU (1) | AU2002326409B2 (en) |
CA (1) | CA2454423A1 (en) |
WO (2) | WO2003008578A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US20040110701A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of zinedin expression |
EP1668155A2 (en) * | 2003-09-24 | 2006-06-14 | Oncotherapy Science, Inc. | Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc) |
EP2363480A3 (en) * | 2004-01-20 | 2015-10-07 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US20070269378A1 (en) * | 2004-06-18 | 2007-11-22 | Exelixis Inc. | Nadks as Modifiers of Branching Morphogenesis and Methods of Use |
WO2006094029A2 (en) * | 2005-02-28 | 2006-09-08 | Kosan Biosciences Incoporated | Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin |
US8076061B2 (en) | 2007-09-07 | 2011-12-13 | Ascentgene, Inc. | Method and composition for cancer diagnosis and treatment |
CN102323247A (en) * | 2008-09-07 | 2012-01-18 | 苏州爱生基因有限公司 | Method for screening drug for treating or preventing cancer |
CN102274490A (en) * | 2008-09-07 | 2011-12-14 | 苏州爱生基因有限公司 | Medicament for treating or preventing cancer |
CN102274489A (en) * | 2008-09-07 | 2011-12-14 | 苏州爱生基因有限公司 | Medicine for treating and preventing cancers |
US20120252028A1 (en) | 2009-08-14 | 2012-10-04 | Michael Shtulman | Target genes for cancer therapy |
KR102050469B1 (en) | 2011-04-01 | 2019-12-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
CN103906838A (en) | 2011-10-25 | 2014-07-02 | Isis制药公司 | Antisense modulation of GCCR expression |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0881300A2 (en) * | 1997-05-30 | 1998-12-02 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions |
US5998136A (en) * | 1996-08-19 | 1999-12-07 | Arcaris, Inc. | Selection systems and methods for identifying genes and gene products involved in cell proliferation |
WO2000055174A1 (en) * | 1999-03-12 | 2000-09-21 | Human Genome Sciences, Inc. | Human prostate cancer associated gene sequences and polypeptides |
WO2001023617A1 (en) * | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | Method for regulating cell growth and assays related thereto |
WO2001040464A1 (en) * | 1999-11-30 | 2001-06-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US566550A (en) * | 1896-08-25 | James timms | ||
US5512660A (en) * | 1987-05-04 | 1996-04-30 | Dana Farber Cancer Institute, Inc. | Purified ICAM-2 and fragment thereof |
US5849536A (en) * | 1990-03-02 | 1998-12-15 | Bio-Technology General Corp. | Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same |
US5942389A (en) | 1990-10-19 | 1999-08-24 | Board Of Trustees Of The University Of Illinois | Genes and genetic elements associated with sensitivity to cisplatin |
US5753432A (en) | 1990-10-19 | 1998-05-19 | Board Of Trustees Of The University Of Illinois | Genes and genetic elements associated with control of neoplastic transformation in mammalian cells |
US5866327A (en) | 1990-10-19 | 1999-02-02 | Board Of Trustees Of The University Of Illinois | Association of kinensin with sensitivity to chemotherapeutic drugs |
US6326488B1 (en) | 1990-10-19 | 2001-12-04 | Board Of Trustees Of University Of Illinois | Gene and genetic elements associated with sensitivity to chemotherapeutic drugs |
US5665550A (en) | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
US5217889A (en) | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
US6268134B1 (en) | 1993-09-07 | 2001-07-31 | Board Of Trustees Of University Of Il | Method and applications for efficient genetic suppressor elements |
US5969124A (en) * | 1992-06-26 | 1999-10-19 | Case Western Reserve University | Nucleotide sequence of L1CAM |
FR2703693B1 (en) | 1993-04-06 | 1995-07-13 | Pasteur Institut | Rapid method of determining a DNA sequence and application to sequencing and diagnosis. |
US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
US5851796A (en) | 1995-06-07 | 1998-12-22 | Yale University | Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes |
US5968773A (en) | 1997-11-14 | 1999-10-19 | Heddle; John A. | System and method for regulation of gene expression |
US6060134A (en) | 1998-05-22 | 2000-05-09 | Flaura Technologies, Llc | Method of preserving botanical specimens |
US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
-
2002
- 2002-02-28 WO PCT/US2002/006254 patent/WO2003008578A2/en active Application Filing
- 2002-02-28 JP JP2003514895A patent/JP2005516586A/en active Pending
- 2002-07-19 CA CA002454423A patent/CA2454423A1/en not_active Abandoned
- 2002-07-19 AU AU2002326409A patent/AU2002326409B2/en not_active Ceased
- 2002-07-19 JP JP2003513493A patent/JP2005514910A/en active Pending
- 2002-07-19 EP EP02761122A patent/EP1427855A4/en not_active Withdrawn
- 2002-07-19 US US10/199,820 patent/US7235403B2/en not_active Expired - Fee Related
- 2002-07-19 WO PCT/US2002/022868 patent/WO2003007884A2/en active IP Right Grant
-
2007
- 2007-02-09 US US11/673,521 patent/US20070154933A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998136A (en) * | 1996-08-19 | 1999-12-07 | Arcaris, Inc. | Selection systems and methods for identifying genes and gene products involved in cell proliferation |
EP0881300A2 (en) * | 1997-05-30 | 1998-12-02 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions |
WO2000055174A1 (en) * | 1999-03-12 | 2000-09-21 | Human Genome Sciences, Inc. | Human prostate cancer associated gene sequences and polypeptides |
WO2001023617A1 (en) * | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | Method for regulating cell growth and assays related thereto |
WO2001040464A1 (en) * | 1999-11-30 | 2001-06-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization |
Non-Patent Citations (2)
Title |
---|
TALUKDER AMJAD H ET AL: "Heregulin induces expression, DNA binding activity, and transactivating functions of basic leucine zipper activating transcription factor 4", CANCER RESEARCH, vol. 60, no. 2, 15 January 2000 (2000-01-15), pages 276 - 281, XP002302778, ISSN: 0008-5472 * |
UENO N T ET AL: "GROWTH SUPPRESSION OF LOW HER-2/NEU-EXPRESSING BREAST CANCER CELL LINE MDA-MB-435 BY TYROSINE KINASE INHIBITOR EMODIN", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 3, no. 3, 1 May 1996 (1996-05-01), pages 509 - 511, XP000672384, ISSN: 1021-335X * |
Also Published As
Publication number | Publication date |
---|---|
CA2454423A1 (en) | 2003-01-30 |
EP1427855A2 (en) | 2004-06-16 |
AU2002326409B2 (en) | 2007-02-15 |
WO2003007884A2 (en) | 2003-01-30 |
JP2005516586A (en) | 2005-06-09 |
WO2003007884A3 (en) | 2003-11-20 |
WO2003008578A3 (en) | 2003-07-31 |
US20070154933A1 (en) | 2007-07-05 |
US20030180739A1 (en) | 2003-09-25 |
JP2005514910A (en) | 2005-05-26 |
WO2003008578A2 (en) | 2003-01-30 |
US7235403B2 (en) | 2007-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002361908A8 (en) | Methods for identifying marker genes for cancer | |
IL158089A0 (en) | Optimized system and method for finding best fares | |
IL161785A0 (en) | Method for identification of tumor targeting enzymes | |
EP1427855A4 (en) | Method and reagents for identifying gene targets for treating breast cancer | |
EP1680073A4 (en) | Compounds and method for treating cancer | |
AU2002312445A1 (en) | Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression | |
AU2003274972A8 (en) | Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby | |
EP1570084A4 (en) | Methods for identifying functionally related genes and drug targets | |
AU2002353850A8 (en) | Method for distinguishing benign and malignant nodules | |
EP1694364A4 (en) | System for treating and preventing breast cancer | |
IL142340A0 (en) | Methods for identification, diagnosis, and treatment of breast cancer | |
EP1575567A4 (en) | Method and reagents for treating or preventing atherosclerosis and diseases associated therewith | |
EP1372715A4 (en) | Method for treating cancer using a33 specific antibodies and chemotherapeutic agents | |
GB2389532B (en) | The method of treating cancer | |
AU2003256995A1 (en) | Method for identifying cancer risk | |
AU2002258597A1 (en) | Prognostic methods for breast cancer | |
EP1401377A4 (en) | Methods for treating cancer | |
EP1282411A4 (en) | Method of treating cancer | |
AU2002301067A1 (en) | Method and apparatus for gaming scatter feature | |
EP1450839A4 (en) | Method of treating estrogen responsive breast cancer | |
EP1391519A4 (en) | Nonspecific hybridization inhibitors, clinical examination reagents and clinical examination method | |
EP1534317A4 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
AU2003293130A8 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
AU2002306622A1 (en) | Reagents and methods for identifying gene targets for treating cancer | |
GB0203645D0 (en) | System and process for analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040220 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 43/00 B Ipc: 7C 07K 14/00 B Ipc: 7C 12Q 1/68 B Ipc: 7C 12N 15/10 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050228 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090203 |